Allay Therapeutics

Allay Tx is developing a drug-eluting biopolymer for sustained post-operative orthopedic pain management.

allaytx.com
Menlo Park, CA

CEO: Adam Gridley
Arboretum lead: Paul McCreadie

IN THE NEWS
June 5, 2025 in Allay Therapeutics, Home Page, News Page

Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of a $57.5M Series D financing round with leading…
Read More
February 18, 2025 in Allay Therapeutics, Home Page, News Page

Allay Therapeutics Doses First Patients in Phase 2b Trial of ATX101 for Post-Knee Replacement Pain Management

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that the first patient has been dosed in its Phase 2b registration…
Read More